Business
Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences
DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"DUBLIN, Sept. 13, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in three upcoming investor conferences.\nTD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit\nDate: Wednesday, September 20, 2023Location: VirtualCompany management will participate in a fireside chat at 12:40 p.m. PT / 3:40 p.m. ET / 8:40 p.m. IST2023 Cantor Fitzgerald Global Healthcare Conference\nDate: Tuesday, September 26, 2023Location: New York CityCompany management will participate in a fireside chat at 9:25 a.m. PT / 12:25 p.m. ET / 5:25 p.m. ISTBofA Securities 2023 CNS Therapeutics Virtual Conference\nDate: Tuesday, October 3, 2023Location: VirtualCompany management will participate in a fireside chat at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. ISTLive webcasts, where applicable, may be accessed via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. A replay of the webcasts will be archived on the website for 30 days.\nAbout Jazz PharmaceuticalsJazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.\nContacts:\nInvestors: Andrea N. Flynn, Ph.D.Vice President, Head, Investor RelationsJazz Pharmaceuticals [email protected] +353 1 634 3211U.S. +1 650 496 2717\nMedia:Kristin BhavnaniHead of Global Corporate CommunicationsJazz Pharmaceuticals [email protected] +353 1 637 2141U.S. +1 215 867 4948\n\n\n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-thr...